# US 2026/0098042 A1 · Pharmaceutically acceptable acid salt of free base of glp1 receptor agonist, and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098042 A1
- Document ID: US20260098042A1
- Status: Published application
- Kind: A1
- Application number: 19/304,270
- Filed: 2025-08-19
- Published: 2026-04-09
- Earliest claimed: 2020-04-01
- Assignees: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Applicants: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Inventors: Haiwen HU; Li FANG; Fan HU; Xinjie ZHOU; Fenfen CHEN
- Web page: https://patentgrep.com/patent/US20260098042A1

## CPC

- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07C 59/06: Glycolic acid
- C07C 59/255: Tartaric acid
- C07C 59/265: Citric acid
- C07C 309/06: containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
- C07C 309/30: of six-membered aromatic rings substituted by alkyl groups
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides pharmaceutically acceptable acid salts of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl) propionic acid (“OAD2”) and the preparation method thereof. The pharmaceutically acceptable acid salts of OAD2 provided herein may be useful in the treatment of various conditions and metabolic disorders including, but not limited to, type 2 diabetes.

## Claims

### Claim at position 1

-12. (canceled)

### Claim 13

A method of treating obesity in a subject in need thereof, comprising orally administering to the subject a pharmaceutical composition comprising a crystalline form of a salt of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionic acid (OAD2), selected from the group consisting of the following:
crystal form B of hydrochloride salt of OAD2 (form B),
crystal form C of hydrochloride salt of OAD2 (form C),
crystal form C of p-toluenesulfonate salt of OAD2 (form C),
crystal form C of tartrate salt of OAD2 (form C),
crystal form C of citrate salt of OAD2 (form C),
crystal form C of glycollate salt of OAD2 (form C),
crystal form C of methanesulfonate salt of OAD2 (form C),
crystal form C of hydrobromide salt of OAD2 (form C),
crystal form D of hydrobromide salt of OAD2 (form D), and
crystal form C of sulfate salt of OAD2 (form C); and
a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the hydrochloride salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 5.3±0.2°, 9.2±0.2°, 10.3±0.2°, 13.2±0.2°, and 14.8±0.2° as measured using Cu, Kα radiation (form B).

### Claim 15 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the hydrochloride salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 1 (form B).

### Claim 16 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the hydrochloride salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 8.9±0.2°, 11.6±0.2°, 14.3±0.2°, 15.9±0.2°, 21.4±0.2°, and 23.1±0.2° as measured using Cu, Kα radiation (form C).

### Claim 17 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the hydrochloride salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 2 (form C).

### Claim 18 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the p-toluenesulfonate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 4.7±0.2°, 5.4±0.2°, 9.7±0.2°, 13.1±0.2°, 16.4±0.2°, and 18.2±0.2° as measured using Cu, Kα radiation (form C).

### Claim 19 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the p-toluenesulfonate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 3 (form C).

### Claim 20 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the tartrate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 7.8±0.2°, 9.9±0.2°, 10.1±0.2°, and 15.6±0.2° as measured using Cu, Kα radiation (form C).

### Claim 21 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the tartrate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprises substantially the same peaks at the 2θ diffraction angles as shown in FIG. 4 (form C).

### Claim 22 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the citrate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 4.5±0.2°, 6.5±0.2°, and 15.9±0.2° as measured using Cu, Kα radiation (form C).

### Claim 23 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the p-toluenesulfonate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 5 (form C).

### Claim 24 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the glycollate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.0±0.2°, 12.1±0.2°, 13.6±0.2°, 18.2±0.2°, and 24.3±0.2° as measured using Cu, Kα radiation (form C).

### Claim 25 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the glycollate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 6 (form C).

### Claim 26 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the methanesulfonate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.2±0.2°, 12.8±0.2°, 13.8±0.2°, 14.4±0.2°, and 22.2±0.2° as measured using Cu, Kα radiation (form C).

### Claim 27 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the methanesulfonate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 7 (form C).

### Claim 28 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the hydrobromide salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 4.6±0.2°, 15.7±0.2°, and 23.7±0.2° as measured using Cu, Kα radiation (form C).

### Claim 29 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the hydrobromide salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 8 (form C).

### Claim 30 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the hydrobromide salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 4.7±0.2°, 8.8±0.2°, 15.9±0.2°, and 17.8±0.2° (form D).

### Claim 31 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the hydrobromide salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 9 (form D).

### Claim 32 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the sulfate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 3.4±0.2°, 8.7±0.2°, and 15.2±0.2° as measured using Cu, Kα radiation (form C).

### Claim 33 (depends on 13)

The method of claim 13, wherein the crystalline form is a crystalline form of the sulfate salt of OAD2 and is characterized as having an X-ray powder diffraction pattern comprising substantially the same peaks at the 2θ diffraction angles as shown in FIG. 10 (form C).

### Claim 34 (depends on 13)

The method of claim 13, wherein the pharmaceutical composition is formulated as a tablet.

### Claim 35 (depends on 13)

The method of claim 13, wherein the subject is administered between 1 mg and 100 mg of the crystalline form of a salt of OAD2 per day.
